BE2013C038I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C038I2 BE2013C038I2 BE2013C038C BE2013C038C BE2013C038I2 BE 2013C038 I2 BE2013C038 I2 BE 2013C038I2 BE 2013C038 C BE2013C038 C BE 2013C038C BE 2013C038 C BE2013C038 C BE 2013C038C BE 2013C038 I2 BE2013C038 I2 BE 2013C038I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200301129 | 2003-08-05 | ||
| US49545103P | 2003-08-14 | 2003-08-14 | |
| EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2013C038I2 true BE2013C038I2 (hr) | 2023-12-14 |
Family
ID=34117520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C035C BE2013C035I2 (hr) | 2003-08-05 | 2013-06-11 | |
| BE2013C038C BE2013C038I2 (hr) | 2003-08-05 | 2013-06-19 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2013C035C BE2013C035I2 (hr) | 2003-08-05 | 2013-06-11 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US7615532B2 (hr) |
| EP (3) | EP1660531A2 (hr) |
| JP (1) | JP4463814B2 (hr) |
| KR (1) | KR101159559B1 (hr) |
| AU (2) | AU2004261353B2 (hr) |
| BE (2) | BE2013C035I2 (hr) |
| BR (1) | BRPI0413276B8 (hr) |
| CA (1) | CA2531988C (hr) |
| CY (3) | CY1113850T1 (hr) |
| FR (2) | FR13C0035I2 (hr) |
| HU (1) | HUS1300033I1 (hr) |
| IL (1) | IL172980A (hr) |
| LU (2) | LU92213I2 (hr) |
| MX (1) | MXPA06001283A (hr) |
| NO (3) | NO340925B1 (hr) |
| PL (1) | PL2107069T3 (hr) |
| RU (1) | RU2518460C2 (hr) |
| WO (1) | WO2005012347A2 (hr) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2085406A1 (en) * | 2003-07-25 | 2009-08-05 | ConjuChem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
| MXPA06001283A (es) | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
| US20080171695A1 (en) * | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
| EP1846446B1 (en) | 2005-02-02 | 2013-06-26 | Novo Nordisk A/S | Insulin derivatives |
| WO2007074133A2 (en) * | 2005-12-28 | 2007-07-05 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| JP5202338B2 (ja) * | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US8293965B2 (en) | 2006-04-28 | 2012-10-23 | Kimberly-Clark Worldwide, Inc. | Antimicrobial site dressings |
| CA2649235A1 (en) * | 2006-05-09 | 2007-11-15 | Frantisek Hubalek | Insulin derivative |
| ES2553154T3 (es) | 2006-05-09 | 2015-12-04 | Novo Nordisk A/S | Derivado de la insulina |
| CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
| JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
| CN101573133B (zh) * | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
| EP2404934A1 (en) | 2006-09-22 | 2012-01-11 | Novo Nordisk A/S | Protease resistant insulin analogues |
| WO2008132224A2 (en) | 2007-04-30 | 2008-11-06 | Novo Nordisk A/S | Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein |
| EP2164466A1 (en) | 2007-06-01 | 2010-03-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| JP5675347B2 (ja) * | 2007-06-01 | 2015-02-25 | ノボ・ノルデイスク・エー／エス | 安定した非水性薬学的組成物 |
| ES2744384T3 (es) * | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| ES2548304T3 (es) * | 2007-08-15 | 2015-10-15 | Novo Nordisk A/S | Análogos de la insulina que contienen una fracción acilo y alquilenglicol |
| JP5721432B2 (ja) * | 2007-08-15 | 2015-05-20 | ノボ・ノルデイスク・エー／エス | アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン |
| CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
| JP5715418B2 (ja) * | 2007-11-08 | 2015-05-07 | ノボ・ノルデイスク・エー／エス | インスリン誘導体 |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| WO2009112583A2 (en) | 2008-03-14 | 2009-09-17 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
| AU2009226910B2 (en) | 2008-03-18 | 2014-02-06 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
| US8637647B2 (en) | 2008-09-12 | 2014-01-28 | Novo Nordisk A/S | Method of acylating a peptide or protein |
| AU2009309623B9 (en) * | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| CA2748593A1 (en) | 2009-01-23 | 2010-07-29 | Novo Nordisk A/S | Fgf21 derivatives with albumin binder a-b-c-d-e- and their use |
| US8835379B2 (en) | 2009-10-30 | 2014-09-16 | Novo Nordisk A/S | Derivatives of CGRP |
| CA2786953A1 (en) | 2010-01-12 | 2011-07-21 | Florian Anders Foeger | Pharmaceutical compositions for oral administration of insulin peptides |
| WO2011101277A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Conjugated proteins |
| WO2011101261A2 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Purification method |
| US20130143803A1 (en) | 2010-05-10 | 2013-06-06 | Novo Nordisk A/S | Process for the Preparation of Insulin-Zinc Complexes |
| WO2011146974A1 (en) | 2010-05-25 | 2011-12-01 | Monash University | Methods for the synthesis of alkyne-containing dicarba bridges in peptides |
| US8853155B2 (en) * | 2010-06-23 | 2014-10-07 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
| CN102947331B (zh) | 2010-06-23 | 2016-08-03 | 诺沃—诺迪斯克有限公司 | 包含额外的二硫键的胰岛素类似物 |
| JP6013330B2 (ja) | 2010-06-23 | 2016-10-25 | ノヴォ ノルディスク アー／エス | 追加のジスルフィド結合を含有するヒトインスリン |
| CN103154024A (zh) | 2010-10-15 | 2013-06-12 | 诺沃—诺迪斯克有限公司 | 新型n末端修饰的胰岛素衍生物 |
| US20130261051A1 (en) * | 2010-10-27 | 2013-10-03 | Thue Johansen | Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals |
| RU2013123515A (ru) * | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
| JP2013545782A (ja) | 2010-12-14 | 2013-12-26 | ノヴォ ノルディスク アー／エス | 長時間作用型インスリンと組み合わせた速効型インスリン |
| JP2014510516A (ja) | 2011-02-15 | 2014-05-01 | ノヴォ ノルディスク アー／エス | 長時間作用性ｉｌ−１受容体アンタゴニスト |
| AU2012234276A1 (en) * | 2011-03-28 | 2013-08-29 | Novo Nordisk A/S | Novel glucagon analogues |
| JP6030630B2 (ja) | 2011-04-14 | 2016-11-24 | ノヴォ ノルディスク アー／エス | 経口ペプチド送達のための脂肪酸アシル化アミノ酸 |
| WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
| MX354705B (es) * | 2011-09-23 | 2018-03-16 | Novo Nordisk As | Analogos de glucagon novedosos. |
| AU2012350586B2 (en) * | 2011-12-15 | 2017-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Human insulin analogue and acylated derivative thereof |
| US20140357838A1 (en) | 2011-12-21 | 2014-12-04 | Novo Nordisk A/S | N-Terminally Modified Insulin Derivatives |
| AU2013247047A1 (en) | 2012-04-11 | 2014-10-23 | Novo Nordisk A/S | Insulin formulations |
| US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
| EP2844274B1 (en) | 2012-05-01 | 2019-03-20 | Novo Nordisk A/S | Pharmaceutical composition |
| WO2014009316A1 (en) | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| EP2908846A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk A/S | Fatty acid acylated d-amino acids for oral peptide delivery |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| WO2014147141A1 (en) * | 2013-03-20 | 2014-09-25 | Novo Nordisk A/S | Insulin dosing regimen |
| MY174727A (en) | 2013-04-18 | 2020-05-11 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー／エス | 新規投与レジメン |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| JP6499184B2 (ja) | 2013-10-07 | 2019-04-10 | ノヴォ ノルディスク アー／エス | インスリン類似体の新規な誘導体 |
| FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| BR112016016321A2 (pt) | 2014-02-18 | 2017-10-03 | Novo Nordisk As | Derivados de análogos de glucagon estáveis, seus usos, e composição farmacêutica |
| AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| US10570184B2 (en) | 2014-06-04 | 2020-02-25 | Novo Nordisk A/S | GLP-1/glucagon receptor co-agonists for medical use |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| US20180244743A1 (en) | 2015-08-25 | 2018-08-30 | Novo Nordisk A/S | Novel Insulin Derivatives and the Medical Uses Hereof |
| CN108026156A (zh) | 2015-08-25 | 2018-05-11 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
| US10815287B2 (en) | 2016-08-02 | 2020-10-27 | Jiangsu Hengrui Medicine Co., Ltd. | Acylated derivative of human insulin or analogue thereof |
| CN110099719A (zh) | 2016-11-28 | 2019-08-06 | 诺和诺德股份有限公司 | 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素 |
| WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| CN110022935A (zh) | 2016-11-28 | 2019-07-16 | 诺和诺德股份有限公司 | 用于心血管病况的德谷胰岛素 |
| BR112019011761A2 (pt) | 2016-12-16 | 2019-11-05 | Novo Nordisk As | composições farmacêuticas contendo insulina |
| JOP20190273A1 (ar) * | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
| BR112020015238A2 (pt) | 2018-02-09 | 2020-12-29 | Jiangsu Hengrui Medicine Co., Ltd. | Gene precursor otimizado por códon e gene de peptídeo sinal de análogo de insulina humana |
| KR20210016400A (ko) | 2018-05-24 | 2021-02-15 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US20220023391A1 (en) | 2018-06-26 | 2022-01-27 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
| US11566059B2 (en) | 2018-08-08 | 2023-01-31 | Daewoong Pharmaceutical Co., Ltd. | Long-acting insulin analogues and derivatives thereof |
| KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
| KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
| TW202120536A (zh) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| AU2020418205A1 (en) | 2019-12-30 | 2022-08-04 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin derivative |
| EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
| EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
| GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
| US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
| US3868358A (en) | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
| GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
| JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
| FI78616C (fi) | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
| US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
| DE3827533A1 (de) | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
| HUT56857A (en) | 1988-12-23 | 1991-10-28 | Novo Nordisk As | Human insulin analogues |
| NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
| IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
| JP3122128B2 (ja) | 1989-12-21 | 2001-01-09 | ノボ ノルディスク アクティーゼルスカブ | ペプチド製剤 |
| DK45590D0 (hr) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
| JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
| UA41502C2 (uk) | 1991-12-20 | 2001-09-17 | Ново Нордіск А/С | Стабілізований фармацевтичний препарат, який містить гормон росту і гістидин, кристали гормону росту, що містять гістидин, та спосіб їх одержання |
| WO1995007931A1 (en) | 1993-09-17 | 1995-03-23 | Novo Nordisk A/S | Acylated insulin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| AU3562195A (en) | 1994-10-04 | 1996-04-26 | Novo Nordisk A/S | Preparations containing aspb28 human insulin and nicotinamide |
| US5646242A (en) | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
| US5830999A (en) | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
| US6251856B1 (en) | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
| AU720966B2 (en) | 1995-03-17 | 2000-06-22 | Novo Nordisk A/S | Insulin derivatives |
| CN1151842C (zh) | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
| US6451970B1 (en) * | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
| US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US5905140A (en) | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
| WO1998002460A1 (en) * | 1996-07-11 | 1998-01-22 | Novo Nordisk A/S | Selective acylation method |
| US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| ATE264871T1 (de) | 1996-07-26 | 2004-05-15 | Aventis Pharma Gmbh | Insulinderivate mit erhöhter zinkbindung |
| IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
| US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
| DE69834028T2 (de) * | 1997-03-20 | 2006-12-07 | Novo Nordisk A/S | Zinkfreie insulinkristalle für die verwendung in medikamenten, die über die lunge verabreicht werden. |
| AU6611998A (en) | 1997-03-20 | 1998-10-20 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
| DE69806582T2 (de) | 1997-03-20 | 2003-02-13 | Novo Nordisk As | Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker |
| US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
| SI0884053T1 (en) | 1997-06-13 | 2003-02-28 | Eli Lilly And Company | Stable insulin formulations |
| BR9813111A (pt) | 1997-10-24 | 2000-08-15 | Lilly Co Eli | Composições de insulina insolúveis |
| CN1240718C (zh) * | 1997-10-24 | 2006-02-08 | 诺沃挪第克公司 | 人胰岛素衍生物的聚集体 |
| US20020155994A1 (en) | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
| US6451762B1 (en) | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| CO4970787A1 (es) | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| ATE290877T1 (de) | 1998-01-09 | 2005-04-15 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
| US6211144B1 (en) | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
| ATE277630T1 (de) | 1998-10-16 | 2004-10-15 | Novo Nordisk As | Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung |
| JP5149470B2 (ja) | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物 |
| EP1173482A1 (en) | 1999-04-27 | 2002-01-23 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
| GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| EP1412384B1 (en) | 2001-06-28 | 2007-12-26 | Novo Nordisk A/S | Stable formulation of modified glp-1 |
| SK2432004A3 (sk) | 2001-12-20 | 2005-04-01 | Eli Lilly And Company | Inzulínová zlúčenina s protrahovaným účinkom |
| AU2003208316A1 (en) | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
| AU2003236201A1 (en) | 2002-05-07 | 2003-11-11 | Novo Nordisk A/S | Soluble formulations comprising monomeric insulin and acylated insulin |
| US20050232899A1 (en) | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
| US20040002451A1 (en) | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
| KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| NZ539811A (en) | 2002-10-29 | 2008-08-29 | Alza Corp | Solid-state polypeptide particles that facilitate the loading of an implant delivery system with a concentration of stabilised, therapeutic polypeptide sufficiently high to enable delivery of therapeutic doses of the polypeptide over an extended period of time |
| US20040138099A1 (en) | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
| BRPI0407303A (pt) | 2003-02-07 | 2006-02-07 | Ajinomoto Kk | Composição farmacêutica |
| CA2516366A1 (en) | 2003-02-19 | 2004-09-02 | Novartis Ag | Glycorpotein antigen sima135 expressed in metastatic human tumor cells |
| EP1454630B1 (en) | 2003-03-04 | 2010-10-20 | The Technology Development Company Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
| JP4658041B2 (ja) | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチドの液体組成物 |
| US20050054818A1 (en) | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
| MXPA06001283A (es) | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
| CN101955527B (zh) | 2003-08-05 | 2016-04-20 | 诺沃挪第克公司 | 新型胰岛素衍生物 |
| KR20120104619A (ko) | 2003-08-14 | 2012-09-21 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물 |
| EP1663295A2 (en) | 2003-09-01 | 2006-06-07 | Novo Nordisk A/S | Stable formulations of peptides |
| ES2229931B1 (es) | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| EP1687428A1 (en) | 2003-11-14 | 2006-08-09 | Novo Nordisk A/S | Processes for making acylated insulin |
| CA2551510C (en) | 2003-12-23 | 2013-07-30 | Pharmacia Corporation | Stable growth hormone liquid formulation |
| CA2558835C (en) | 2004-03-12 | 2011-06-28 | Biodel, Inc. | Rapid acting drug delivery compositions |
| BRPI0510527A (pt) | 2004-06-01 | 2007-10-30 | Ares Trading Sa | método de estabilização de proteìnas |
| CN101039660B (zh) | 2004-08-12 | 2010-10-06 | 先灵公司 | 稳定的聚乙二醇化干扰素制剂 |
| BRPI0514411B8 (pt) | 2004-08-17 | 2021-05-25 | Regeneron Pharma | formulação, e, método de produzir uma formulação |
| EP1814581B1 (en) | 2004-11-12 | 2016-03-16 | Novo Nordisk A/S | Stable formulations of peptides comprising an acylated glp-1 analogue and a basal insuline |
| CN101060856B (zh) | 2004-11-22 | 2011-01-19 | 诺和诺德公司 | 可溶、稳定的含胰岛素制剂 |
| EP1838290A2 (en) | 2005-01-21 | 2007-10-03 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
| EP1846446B1 (en) * | 2005-02-02 | 2013-06-26 | Novo Nordisk A/S | Insulin derivatives |
| WO2007074133A2 (en) | 2005-12-28 | 2007-07-05 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
| JP5202338B2 (ja) | 2006-02-27 | 2013-06-05 | ノボ・ノルデイスク・エー／エス | 新規インシュリン誘導体 |
| AU2007238114B2 (en) | 2006-04-12 | 2010-10-14 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| CA2649235A1 (en) | 2006-05-09 | 2007-11-15 | Frantisek Hubalek | Insulin derivative |
| ES2744384T3 (es) | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
| ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja active Active
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en active Active
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko active Protection Beyond IP Right Term
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en active Active
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en active Active
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-07-04 CY CY2013027C patent/CY2013027I1/el unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-05 FR FR13C0038C patent/FR13C0038I1/fr active Active
- 2013-07-08 CY CY2013029C patent/CY2013029I2/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown